
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9403772/publications.pdf Version: 2024-02-01



SEMDA DAVDAS

#	Article	IF	CITATIONS
1	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, The, 2021, 397, 592-604.	6.3	441
2	Granulocytic sarcoma: 32 cases and review of the literature. Leukemia and Lymphoma, 2006, 47, 2527-2541.	0.6	247
3	Bone marrow necrosis: Clinicopathologic analysis of 20 cases and review of the literature. American Journal of Hematology, 2002, 70, 300-305.	2.0	133
4	Epstein-Barr Virus–Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far. Oncologist, 2011, 16, 87-96.	1.9	99
5	Management of adverse effects/toxicity of ibrutinib. Critical Reviews in Oncology/Hematology, 2019, 136, 56-63.	2.0	95
6	Sweet's syndrome associated with G-CSF. British Journal of Haematology, 1993, 85, 191-192.	1.2	85
7	Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Medical Oncology, 2016, 33, 93.	1.2	82
8	Efficacy of pneumatic compression and low-level laser therapy in the treatment of postmastectomy lymphoedema: a randomized controlled trial. Clinical Rehabilitation, 2009, 23, 117-124.	1.0	73
9	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Annals of Hematology, 2015, 94, 1545-1552.	0.8	73
10	Prognostic Significance of Microvessel Density and Vascular Endothelial Growth Factor (VEGF) Expression in non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2003, 44, 2089-2093.	0.6	67
11	PRAME mRNA levels in cases with acute leukemia: Clinical importance and future prospects. American Journal of Hematology, 2005, 79, 257-261.	2.0	66
12	Leukaemia cutis and leukaemic vasculitis. British Journal of Dermatology, 2000, 143, 773-779.	1.4	65
13	Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables. Medical Oncology, 2016, 33, 34.	1.2	60
14	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Oncology, 2017, 28, 2496-2502.	0.6	60
15	Clinical significance and frequency of Blastocystis hominis in Turkish patients with hematological malignancy. Acta Medica Okayama, 2000, 54, 133-6.	0.1	49
16	Sweet's syndrome: A revisit for hematologists and oncologists. Critical Reviews in Oncology/Hematology, 2013, 86, 85-95.	2.0	47
17	Social Support and Hopelessness in Patients with Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 571-578.	O.5	47
18	Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Annals of Oncology, 2003, 14, 1045-1050.	0.6	44

#	Article	IF	CITATIONS
19	Sweet's syndrome accompanying leukaemia: seven cases and review of the literature. Leukemia Research, 2000, 24, 83-86.	0.4	42
20	Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leukemia Research, 2008, 32, 1424-1430.	0.4	40
21	Antioxidant enzyme levels in cases with gastrointesinal cancer. European Journal of Internal Medicine, 2009, 20, 403-406.	1.0	39
22	Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study. Journal of Oncology Pharmacy Practice, 2016, 22, 242-247.	0.5	39
23	Vasculitis and Leukemia. Leukemia and Lymphoma, 2000, 40, 105-112.	0.6	38
24	Dasatinib, large granular lymphocytosis, and pleural effusion: Useful or adverse effect?. Critical Reviews in Oncology/Hematology, 2014, 89, 242-247.	2.0	38
25	Megadose methylprednisolone pulse therapy in adult idiopathic thrombocytopenic purpura. Lancet, The, 1991, 337, 56.	6.3	36
26	Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 226, 25-29.	0.5	36
27	Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey. British Journal of Cancer, 1999, 80, 1303-1305.	2.9	35
28	Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leukemia Research, 2009, 33, 1627-1635.	0.4	34
29	Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases. Acta Orthopaedica Et Traumatologica Turcica, 2017, 51, 1-6.	0.3	32
30	Prognostic importance of survivin, Ki-67, and topoisomerase Ilα in ovarian carcinoma. Archives of Gynecology and Obstetrics, 2014, 289, 393-398.	0.8	31
31	PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Leukemia Research, 2007, 31, 365-369.	0.4	30
32	Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. Biomarkers in Medicine, 2019, 13, 1565-1575.	0.6	29
33	IDA-FLAG Regimen for the Therapy of Primary Refractory and Relapse Acute Leukemia: A Single-Center Experience. American Journal of Therapeutics, 2006, 13, 389-393.	0.5	28
34	Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. European Journal of Internal Medicine, 2009, 20, 96-99.	1.0	28
35	The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leukemia and Lymphoma, 2009, 50, 366-373.	0.6	28
36	<i>Helicobacter pylori</i> eradication in gastric diffuse large B cell lymphoma. World Journal of Gastroenterology, 2015, 21, 3773.	1.4	28

#	Article	IF	CITATIONS
37	Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Annals of Hematology, 2015, 94, 415-420.	0.8	27
38	Adenosine deaminase activity in patients with ovarian neoplasms. Archives of Gynecology and Obstetrics, 2012, 286, 155-159.	0.8	26
39	Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin's lymphoma. American Journal of Hematology, 2004, 76, 252-257.	2.0	25
40	Granulocytic sarcoma of the heart: Extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leukemia and Lymphoma, 2005, 46, 1081-1084.	0.6	25
41	Survivin and EPR-1 expression in acute leukemias: Prognostic significance and review of the literature. Leukemia Research, 2007, 31, 1495-1501.	0.4	25
42	Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC). International Journal of Clinical Oncology, 2019, 24, 168-178.	1.0	25
43	Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-Hodgkin's lymphoma. American Journal of Hematology, 2003, 74, 89-93.	2.0	24
44	All trans retinoic acid as the possible cause of necrotizing vasculitis. Leukemia Research, 1998, 22, 655-657.	0.4	23
45	Primitive neuroectodermal tumor of the kidney: a rare entity. International Urology and Nephrology, 2001, 33, 449-451.	0.6	23
46	Hepatitis C virus and lymphoma. Critical Reviews in Oncology/Hematology, 2015, 93, 246-256.	2.0	23
47	Primary central nervous system lymphoma: essential points in diagnosis and management. Medical Oncology, 2017, 34, 61.	1.2	23
48	Vasculitis Associated with All Trans Retinoic Acid (ATRA) in a Case with Acute Promyelocytic Leukemia. Leukemia and Lymphoma, 2003, 44, 547-548.	0.6	22
49	Systematic review/Meta-analysis The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. Archives of Medical Science, 2015, 4, 708-714.	0.4	22
50	Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer. Archives of Gynecology and Obstetrics, 2019, 300, 377-382.	0.8	22
51	MUC1 expression in plasmacytoma. Leukemia Research, 2001, 25, 221-225.	0.4	21
52	Sickle Cell Anemia and Hematological Neoplasias. Leukemia and Lymphoma, 2002, 43, 1431-1434.	0.6	21
53	Successful Rituximab Therapy for Hemolytic Anemia Associated with Relapsed Splenic Marginal Zone Lymphoma with Leukemic Phase. Leukemia and Lymphoma, 2003, 44, 2165-2166.	0.6	20
54	Fludarabine-induced hemolytic anemia: successful treatment by rituximab. The Hematology Journal, 2004, 5, 81-83.	2.0	20

#	Article	IF	CITATIONS
55	Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leukemia and Lymphoma, 2012, 53, 1706-1708.	0.6	20
56	Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology, 2020, 99, 2565-2576.	0.8	19
57	Social support and hopelessness in patients with breast cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 571-8.	0.5	19
58	The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up. Nuclear Medicine Communications, 2010, 31, 59-66.	0.5	18
59	Tafro syndrome: Critical review for clinicians and pathologists. Critical Reviews in Oncology/Hematology, 2018, 128, 88-95.	2.0	18
60	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer, 2020, 148, 48-54.	0.9	18
61	Non-hodgkin's lymphomas in turkey. Cancer, 1988, 62, 1653-1657.	2.0	17
62	Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leukemia and Lymphoma, 2007, 48, 389-395.	0.6	17
63	Capecitabine-Induced Hypertriglyceridemia and Hyperglycemia: Two Cases. Pharmacology, 2012, 90, 212-215.	0.9	17
64	PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma. Acta Haematologica, 2015, 134, 199-207.	0.7	17
65	Pancreatic Carcinoma, Thrombosis and Mean Platelet Volume: Single Center Experience from the Southeast Region of Turkey. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9143-9146.	0.5	17
66	Young age MDS: Differences between Western and Eastern countries. Leukemia Research, 2006, 30, 362.	0.4	16
67	Granulocytic sarcoma as the cause of giant abdominal mass: diagnosis by fine needle aspiration and review of the literature. Leukemia Research, 2000, 24, 267-269.	0.4	15
68	Granulomatous reaction after chemotherapy for Hodgkin's disease. Leukemia Research, 2002, 26, 967-970.	0.4	15
69	Serous retinal detachment in a case with chronic lymphocytic leukemia: no response to systemic and local treatment. Leukemia Research, 2003, 27, 557-559.	0.4	15
70	Mucormycosis of the tongue in a patient with acute lymphoblastic leukemia: a possible relation with use of a tongue depressor. American Journal of Medicine, 2003, 114, 618-620.	0.6	15
71	Extramedullary Relapse in the Pleura in Acute Promyelocytic Leukemia. Leukemia and Lymphoma, 2003, 44, 189-191.	0.6	15
72	Management of hemopoietic neoplasias during pregnancy. Critical Reviews in Oncology/Hematology, 2016, 104, 52-64.	2.0	15

#	Article	IF	CITATIONS
73	Vascular Endothelial Growth Factor (VEGF) Expression in Plasmacytoma. Leukemia and Lymphoma, 2002, 43, 139-143.	0.6	14
74	Gravin gene expression in acute leukaemias: Clinical importance and review of the literature. Leukemia and Lymphoma, 2007, 48, 1167-1172.	0.6	14
75	Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leukemia Research, 2008, 32, 243-250.	0.4	14
76	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turkish Journal of Haematology, 2013, 30, 351-358.	0.2	14
77	PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus. Journal of Clinical Pathology, 2018, 71, 637-641.	1.0	14
78	Ovarian Granulocytic Sarcoma. Leukemia and Lymphoma, 2004, 45, 183-185.	0.6	13
79	Lymphadenopathy in adult-onset Still?s disease mimicking peripheral T-cell lymphoma. Clinical Rheumatology, 2004, 23, 81-82.	1.0	13
80	The Pan ancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	1.9	13
81	VEGF-C expression in breast cancer: Clinical importance. Advances in Therapy, 2005, 22, 368-380.	1.3	12
82	Avascular Osteonecrosis and Accompanying Anemia, Leucocytosis, and Decreased Bone Mineral Density in Renal Transplant Recipients. Transplantation Proceedings, 2011, 43, 863-866.	0.3	12
83	Younger age observation IN myelodysplastic syndrome. Leukemia Research, 1996, 20, 367.	0.4	11
84	Bilateral choroidal infiltration from indolent non-Hodgkin's lymphoma: A rapid course with poor prognosis. Leukemia and Lymphoma, 2005, 46, 615-617.	0.6	11
85	Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial. Leukemia Research, 2011, 35, 340-345.	0.4	11
86	Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?. Annals of Oncology, 2016, 27, 1650-1651.	0.6	11
87	Small cell carcinoma of the larynx. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 1994, 15, 375-378.	0.6	10
88	Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia. Leukemia Research, 2006, 30, 364.	0.4	10
89	Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia. Medical Oncology, 2012, 29, 2937-2943.	1.2	10
90	Evaluation of Endometrial Thickness and Bone Mineral Density Based on CYP2D6 Polymorphisms in Turkish Breast Cancer Patients Receiving Tamoxifen Treatment. Pharmacology, 2014, 94, 183-189.	0.9	10

#	Article	IF	CITATIONS
91	DNA repair gene polymorphisms in B cell non-Hodgkin's lymphoma. Tumor Biology, 2015, 36, 2155-2161.	0.8	10
92	Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1169-1173.	0.5	10
93	Transfusion-associated graft-versus-host disease. European Journal of Internal Medicine, 2006, 17, 151-156.	1.0	9
94	Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication. Mycoses, 2007, 50, 135-139.	1.8	9
95	SIADH induced by amiodarone in a patient with heart failure. International Journal of Clinical Practice, 2008, 62, 337-337.	0.8	9
96	Hyponatremia Is Not a Rare Adverse Event in Bortezomib-Treated Patients. Chemotherapy, 2011, 57, 434-436.	0.8	9
97	Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. Cancer Investigation, 2021, 39, 473-481.	0.6	9
98	Serum levels of tumor necrosis factor in squamous cell carcinoma of the head and neck. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 1994, 15, 281-285.	0.6	8
99	Morphologic evaluation of the effect of denosumab on giant cell tumors of bone and a new grading scheme. Polish Journal of Pathology, 2016, 4, 392-397.	0.1	8
100	Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naìve breast cancer: real-life practice outcomes. Cancer Chemotherapy and Pharmacology, 2019, 83, 131-143.	1.1	8
101	Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. European Urology Focus, 2021, 7, 1061-1066.	1.6	8
102	Postmastectomy Malignant Lymphoma. Leukemia and Lymphoma, 2000, 36, 417-420.	0.6	7
103	Lymphomatous Skin Infiltration at the Site of Previous Varicella Zoster Virus Infection in a Patient with T Cell Lymphoma. Leukemia and Lymphoma, 2000, 37, 229-232.	0.6	7
104	Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs. Leukemia and Lymphoma, 2008, 49, 1644-1645.	0.6	7
105	PET CT imaging in extramedullary hematopoiesis and lung cancer surprise in a case with thalassemia intermedia. Turkish Journal of Haematology, 2011, 28, 60-62.	0.2	7
106	Bone Disease and Serum Fibroblast Growth Factor-23 Levels in Renal Transplant Recipients. Transplantation Proceedings, 2016, 48, 2040-2045.	0.3	7
107	Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 244, 51-55.	0.5	7
108	Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e474-e484.	0.2	7

#	Article	IF	CITATIONS
109	Different glomerular pathologies in sickle cell anemia. Clinical Nephrology, 2004, 62, 400.	0.4	7
110	Plasma Levels of Tumor Necrosis Factor Alpha during Hemodialysis. Nephron, 1991, 57, 477-478.	0.9	6
111	p53 Protein Expression in Gastrointestinal Lymphomas. Oncology, 1997, 54, 84-87.	0.9	6
112	Hepatitis B Virus Reactivation During Fludarabine Therapy in Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2003, 44, 1249-1250.	0.6	6
113	Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity. Medical Oncology, 2012, 29, 2159-2165.	1.2	6
114	Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. Clinical Genitourinary Cancer, 2016, 14, e347-e353.	0.9	6
115	The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen. Journal of Gastrointestinal Cancer, 2021, 52, 249-255.	0.6	6
116	Sarcoid-like reaction in cases treated by checkpoint inhibitors. Medical Oncology, 2021, 38, 29.	1.2	6
117	Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma. Leukemia Research, 2021, 107, 106586.	0.4	6
118	Primitive uterine neuroectodermal tumours: Two case reports. Tâ^šÂºrk Jinekoloji Ve Obstetrik Dernei Dergisi, 2015, 12, 185-187.	0.3	6
119	A Unique Case of Merkel Cell Carcinoma with Ovarian Metastasis. Balkan Medical Journal, 2015, 31, 356-359.	0.3	6
120	Retrospective Analysis of 498 Primary Soft Tissue Sarcomas in a Single Turkish Centre. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4125-4128.	0.5	6
121	Chronic myeloid leukemia in a patient with colon adenocarcinoma. Haematologia, 2002, 32, 501-3.	0.2	6
122	Different glomerulopathies accompanying non-small-cell lung cancer. Mount Sinai Journal of Medicine, 2005, 72, 279-81.	1.9	6
123	Carbamazepine and Multiple Myeloma: Possible Interaction. Turkish Journal of Haematology, 2013, 30, 83-84.	0.2	5
124	The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma. Archives of Gynecology and Obstetrics, 2015, 292, 923-929.	0.8	5
125	Evaluation of lipid profiles in patients treated with capecitabine. Turkish Journal of Medical Sciences, 2017, 47, 1206-1209.	0.4	5
126	Ferritin levels in malignant effusions: a useful marker?. European Journal of Cancer & Clinical Oncology, 1990, 26, 919.	0.9	4

#	Article	IF	CITATIONS
127	Intracellular Glutathione Content in Leukemias. Oncology, 1995, 52, 112-115.	0.9	4
128	Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?. Leukemia and Lymphoma, 2006, 47, 2412-2413.	0.6	4
129	Dramatic Improvement of Pulmonary Mucormycosis After Surgery in a Case Without Immunodeficiency. Infectious Diseases in Clinical Practice, 2006, 14, 403-405.	0.1	4
130	Feasibility of FLAG-IDA regimen in cases with relapsed/refractory acute leukemia cases. Annals of Hematology, 2006, 85, 63-63.	0.8	4
131	Motor Neuron Disease Associated with Multiple Myeloma. International Journal of Neuroscience, 2008, 118, 337-341.	0.8	4
132	Hairy Cell Leukemia and Bladder Cancer in a Patient: Relation with Dye Exposure and Review of the Literaure. Advances in Hematology, 2009, 2009, 1-2.	0.6	4
133	Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib. Turkish Journal of Haematology, 2011, 28, 232-234.	0.2	4
134	Abdominal actinomycosis with multiple myeloma: A case report. Oncology Letters, 2014, 8, 1876-1878.	0.8	4
135	Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Journal of Cancer Education, 2020, 35, 69-75.	0.6	4
136	Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Annals of Hematology, 2020, 99, 301-307.	0.8	4
137	Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2145-2152.	1.2	4
138	Super Scan Caused by Parathyroid Carcinoma Observed Both in 18F-FDG PET/CT Scan and Tc-99m MDP Bone Scintigraphy. Molecular Imaging and Radionuclide Therapy, 2017, 26, 116-119.	0.3	4
139	Inflammatory Markers Predicting Pathological Complete Response in Cases with Breast Cancer Treated by Neoadjuvant Chemotherapy. The Journal of Breast Health, 2020, 16, 229-234.	0.4	4
140	Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases. Turkish Journal of Haematology, 2020, 37, 220-225.	0.2	4
141	Alterations of ghrelin with weights and correlation among ghrelin, cytokine and survival in patients receiving chemoradiotherapy for gastrointestinal cancers. International Journal of Clinical and Experimental Medicine, 2015, 8, 876-82.	1.3	4
142	p53 Protein Expression in Leukemias. Acta Oncológica, 1995, 34, 23-26.	0.8	3
143	The Association of Thyrotoxicosis and Chronic Lymphoproliferative Disorders. Leukemia and Lymphoma, 2000, 38, 131-135.	0.6	3
144	Granulomatous orchitis mimicking Hodgkin's lymphoma relapse. The Hematology Journal, 2003, 4, 370-371.	2.0	3

#	Article	IF	CITATIONS
145	Prostatic Hypertrophy and Prostatic Infiltration in Small Lymphocytic Lymphoma. Leukemia and Lymphoma, 2004, 45, 201-202.	0.6	3
146	Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?. Leukemia Research, 2009, 33, 566-567.	0.4	3
147	Castleman-like reaction due to toxic substance ingestion. European Journal of Internal Medicine, 2009, 20, 328-330.	1.0	3
148	Sweet Syndrome in a Patient with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Curious Lymphocyte/Neutrophil Fluctuations. Turkish Journal of Haematology, 2013, 30, 413-415.	0.2	3
149	The Role of Radiotherapy Among the Therapeutic Options for Castleman's Disease. Turkish Journal of Haematology, 2014, 31, 197-8.	0.2	3
150	Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer, 2015, 22, 480-485.	1.3	3
151	P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey. Journal of Thoracic Oncology, 2019, 14, S558-S559.	0.5	3
152	Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos) Tj ETQq0 0 0 European Journal of Cancer Care, 2020, 29, e13296.	0 rgBT /Ov 0.7	verlock 10 Tf 5 3
153	An Interesting Case: Sunitinib-Induced Microangiopathic Hemolytic Anemia and Nephrotic Syndrome. Turkish Journal of Haematology, 2021, 38, 163-165.	0.2	3
154	Coexistence of tuberous sclerosis complex and malignant melanoma. Singapore Medical Journal, 2013, 54, e233-5.	0.3	3
155	Colchicine therapy in amyloidosis related with plasmacytic castleman disease presenting with nephrotic syndrome. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015, 26, 992.	0.4	3
156	Myeloid Neoplasia and Lymphoblastic Lymphoma with Eosinophilia After Radioactive Iodine: A Case Report. Balkan Medical Journal, 2018, 35, 199-202.	0.3	3
157	Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer. Gaziantep Medical Journal, 2011, 17, 67.	0.2	3
158	Prevalence of cytogenetic abnormalities in chronic lymphocytic leukemia in the southern part of Turkey. Indian Journal of Cancer, 2017, 54, 572.	0.2	3
159	Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung. International Journal of Clinical and Experimental Pathology, 2015, 8, 9760-71.	0.5	3
160	Interesting morphologic finding in T-cell acute lymphoblastic leukemia. , 1999, 21, 55-56.		2
161	Scrotal ulceration associated with ATRA. American Journal of Hematology, 2004, 77, 206-207.	2.0	2
162	Anti-angiogenic strategies will be a revolution in lymphoma?. Leukemia Research, 2010, 34, 552.	0.4	2

#	Article	IF	CITATIONS
163	Smudge cells: Very old history and new conclusions. Leukemia Research, 2010, 34, 1680.	0.4	2
164	Bendamustine and rituximab is effective and cost-effective in older cases with aggressive lymphomas?. Annals of Oncology, 2011, 22, 2694-2695.	0.6	2
165	Extramedullary Myeloid Tumor Involving the Pancreas: A Case Report and Review of the Literature. Turkish Journal of Haematology, 2014, 31, 295-300.	0.2	2
166	Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma. Annals of Hematology, 2016, 95, 145-146.	0.8	2
167	Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and rewiev of the literature. Journal of Oncological Science, 2018, 4, 56-59.	0.1	2
168	Pancreatic plasmacytoma: A rare but important entity for gastroenterologists, oncologists and hematologists. Journal of Oncological Science, 2019, 5, 109-111.	0.1	2
169	Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas. Ginekologia Polska, 2021, 92, 278-283.	0.3	2
170	Long-Term Effectiveness of Combined Intermittent Pneumatic Compression Plus Low-Level Laser Therapy in Patients with Postmastectomy Lymphedema: A Randomized Controlled Trial. Lymphatic Research and Biology, 2022, 20, 175-184.	0.5	2
171	Fludarabine as the possible cause of acute myelofibrosis. The Hematology Journal, 2004, 5, 283-284.	2.0	2
172	Lokal ileri evre meme kanserli hastalarda neoadjuvan kemoterapinin ER, PR, c-erb2, VEGF ve Ki-67 üzerine etkisi. Cukurova Medical Journal, 2019, 44, 226-231.	0.1	2
173	Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Medical Journal, 2020, 37, 104-107.	0.3	2
174	Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Journal of King Abdulaziz University, Islamic Economics, 2004, 25, 1587-92.	0.5	2
175	Analysis of breast cancer classification robustness with radiomics feature extraction and deep learning techniques. Expert Systems, 0, , .	2.9	2
176	DNA ploidy, proliferative activity, and concanavalin A reactivity in breast cancer. Journal of Surgical Oncology, 1994, 56, 21-24.	0.8	1
177	An unusual amebic localization on the right hip. Infection, 1995, 23, 124-125.	2.3	1
178	HCV and tumors of the immune system. Leukemia Research, 2002, 26, 1141.	0.4	1
179	Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 277-277.	1.3	1
180	Stewart-Treves Syndrome: Questionable Response to Weekly Paclitaxel. Chemotherapy, 2010, 56, 66-68.	0.8	1

#	Article	IF	CITATIONS
181	Late Onset Epstein Barr Virus Seropositive Posttransplant Lymphoproliferative Disorder in Two Renal Transplant Receivers. Turkish Journal of Haematology, 2013, 30, 315-320.	0.2	1
182	The Permanent Improvement of Proteinuria and Renal Failure With Colchicine and Enalapril in a Leukemic Patient With Renal Amyloidosis Secondary to Ankylosing Spondylitis. American Journal of Therapeutics, 2013, 20, 344-346.	0.5	1
183	Acute promyelocytic leukemia after anthracycline containing chemotherapy for breast cancer: Case report and review of the literature. Journal of Oncological Science, 2018, 4, 62-64.	0.1	1
184	Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ≥Vgpr Responses Among Immunomodulatory / Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e242-e243.	0.2	1
185	Orbital extramedullary leukaemia is not a rare entity. British Journal of Haematology, 2019, 186, e6-e7.	1.2	1
186	Prognosis Trend of Grade 2 Endometrioid Endometrial Carcinoma: Toward Grade 1 or 3?. Pathology and Oncology Research, 2020, 26, 2351-2356.	0.9	1
187	Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG). Indian Journal of Hematology and Blood Transfusion, 2020, 36, 640-645.	0.3	1
188	IPS-3 Validation in 1012 cases with classical hodgkin lymphoma. Leukemia Research, 2021, 102, 106519.	0.4	1
189	Severe Lymphocytosis in a Case with Diffuse Large B Cell Lymphoma Treated by Ibrutinib. Turkish Journal of Haematology, 2021, 38, 337-338.	0.2	1
190	Cerebral MRI Mimicking Pachymeningeal Involvement Associated with Intrathecal Treatment. Turkish Journal of Haematology, 2020, 37, 308-309.	0.2	1
191	Atypical Radiologic Image Characterized by Cavitary Lung Lesions in a Case of Hodgkin Lymphoma. Turkish Journal of Haematology, 2019, 36, 60-61.	0.2	1
192	Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer Journal of Clinical Oncology, 2019, 37, e16075-e16075.	0.8	1
193	Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG)ÂStudy. Cancer Investigation, 2022, 40, 199-209.	0.6	1
194	GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor. European Journal of Mass Spectrometry, 2022, 28, 12-24.	0.5	1
195	Cutaneous lesions and chronic myelocytic leukemia (CML) in progression. Annals of Hematology, 2002, 81, 178-178.	0.8	Ο
196	Post transplant lymphoproliferative disease: detection of tumor by Tc99m sestaMIBI and treatment with rituximab. Bone Marrow Transplantation, 2005, 35, 317-318.	1.3	0
197	Hepatitis C virus infection and lymphomas. International Journal of Cancer, 2005, 113, 338-338.	2.3	0
198	Glomerular Disease in Patients with Malignant Disease: Four Cases and Review of Literature. Renal Failure, 2005, 27, 1-6.	0.8	0

#	Article	IF	CITATIONS
199	Hepatitis C virus and lymphoma: which is usefulserum or tissue?. Journal of Clinical Pathology, 2010, 63, 1040-1040.	1.0	0
200	Coarctation of the aorta diagnosed by physical examination after imaging. Herz, 2013, 38, 679-682.	0.4	0
201	Energy drinks and chemotherapy: Can these products cause detrimental effects in cancer patients receiving chemotherapy?. European Journal of Internal Medicine, 2013, 24, e3-e4.	1.0	0
202	A Case with Hypothyrodism Following Autologous Stem Cell Transplantation. Turkish Journal of Haematology, 2013, 30, 221-222.	0.2	0
203	Now is not the time to just talk, but to take action. Journal of Oncological Science, 2016, 1, xii.	0.1	0
204	Coexistence of hypertrophic osteoarthropathy and myelofibrosis. Revista Brasileira De Reumatologia, 2017, 57, 472-474.	0.7	0
205	Nivolumab for relapsed or refractory <scp>H</scp> odgkin lymphoma: Experience in <scp>T</scp> urkey. Hematological Oncology, 2017, 35, 321-323.	0.8	0
206	Meta-analysis of the effect of rituximab in the treatment of primary central nervous system lymphoma. Annals of Oncology, 2017, 28, v112.	0.6	0
207	Lymphocytic thyroiditis simulating thyroid cancer biochemically, radiologically and pathologically. Journal of Oncological Science, 2018, 4, 114-115.	0.1	0
208	Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study. Archives of Medical Science, 2021, 17, 920-927.	0.4	0
209	Are Uterine Grade 3 Endometrioid Adenocarcinoma and Carcinosarcoma Really Clinically Similar?. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.1	0
210	Clinicopathological Factors Determining the Pathological Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer. Namık Kemal Tıp Dergisi, 2021, 9, 179-183.	0.0	0
211	Programmed death-1 (PD-1) and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma Journal of Clinical Oncology, 2014, 32, e19514-e19514.	0.8	0
212	The evaluation of endometrial thickness and bone mineral density based on CYP2D6 polymorphisims in Turkish breast cancer patients receiving tamoxifen treatment Journal of Clinical Oncology, 2014, 32, e11559-e11559.	0.8	0
213	The effect of platinum and docetaxel based chemoradiotherapy on survival in locally advanced unresectable non-small cell lung cancer patients Journal of Clinical Oncology, 2015, 33, e18538-e18538.	0.8	0
214	Changes in PD-1 and PD-L1 Expression in Cases with Hodgkin Lymphoma after Chemotherapy. Blood, 2015, 126, 4998-4998.	0.6	0
215	Effectiveness of bendamustine in relapse or refractory lymphoma cases: A report from Turkey—The Turkish Oncology Group (TOG) study Journal of Clinical Oncology, 2017, 35, e19027-e19027.	0.8	0
216	EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC) Journal of Clinical Oncology, 2018, 36, e12584-e12584.	0.8	0

#	Article	IF	CITATIONS
217	Merkel cell carcinoma in Turkey: A multicentric study Journal of Clinical Oncology, 2018, 36, e21591-e21591.	0.8	0
218	Plevral tutulumu olan plazma hücre neoplazisi. Cukurova Medical Journal, 2018, 43, 498-499.	0.1	0
219	Multiple myelomda kromozomal aberasyonlar: klinik sonuçlar ve bortezomib' e yanıt. Cukurova Medical Journal, 2019, 44, 1-1.	0.1	0
220	Clinic, Prognostic and Predictive Value of Circulating Tumor DNA in Lymphomas. LLM Dergi, 2019, 3, 45-50.	0.0	0
221	Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey. , 2020, , .		0
222	Obez endometroid endometrial kanserli olgulara pelvik lenfadenektomiye paraaortik lenfadenektomi eklenmesinin sağkalıma etkisi. Cukurova Medical Journal, 2020, 45, 134-140.	0.1	0
223	Meme kanserinde PRAME (preferentially expressed antigen of melanoma) ekspresyonunun prognostik önemi. Cukurova Medical Journal, 2020, 45, 1202-1209.	0.1	0
224	Commentary. Journal of Neurosciences in Rural Practice, 2012, 3, 100.	0.3	0
225	Oncologists' Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG). Asian Pacific Journal of Cancer Prevention, 2017, 18, 3149-3155.	0.5	0
226	Dose-Adjusted R-EPOCH Therapy for Aggressive Lymphoma: A single center experience. Medical Science and Discovery, 2020, 7, 691-695.	0.1	0
227	Podocyte Injury in Cases with Newly Diagnosed Multiple Myeloma. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2021, 32, 722.	0.4	0
228	The effect of <i>Paraoxonase</i> gene polymorphisms and paraoxonase enzyme activity on Non-Hodgkin lymphoma. Nucleosides, Nucleotides and Nucleic Acids, 2022, , 1-14.	0.4	0
229	Prognostic and predictive value of EZH2 expression and the tumor immune microenvironment in Merkel cell carcinoma. Polish Journal of Pathology, 2021, 72, 140-147.	0.1	0
230	Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. Journal of Chemotherapy, 2022, , 1-8.	0.7	0
231	Jugular Paraganglioma Presenting With A Tumor Thrombus Extending From Posterior Fossa To Right Atrium And Multiple Skeletal Metastases. Current Medical Imaging, 2022, 18, .	0.4	Ο